Ignite Creation Date:
2024-05-05 @ 5:27 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00469664
Status:
UNKNOWN
Last Update Posted:
2008-05-21
First Post:
2007-05-02
Brief Title:
Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia
Sponsor:
Research Foundation for Mental Hygiene Inc
Organization:
Research Foundation for Mental Hygiene Inc
Study Overview
Official Title:
A Double Blind Placebo Controlled Study of Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia
Status:
UNKNOWN
Status Verified Date:
2008-05
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Guanfacine
Brief Summary:
Our overall aim is to determine if the administration of guanfacine in combination with aripiprazole olanzapine quetiapine andor risperidone is significantly more effective than any of those medications alone in treating some of the cognitive impairment in schizophrenia
Detailed Description:
The proposed study is a double blind placebo controlled parallel designed investigation comparing the effect of one of four atypical antipsychotics aripiprazole olanzapine quetiapine andor risperidone treatment alone to treatment with one of these in addition to treatment with guanfacine to maximum dose of 30 mg per day on a cognitive task performance in schizophrenic patients The study will take place over fourteen weeks Patients will receive study medication for the last ten weeks of the protocol
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 99-621 | None | None | None |